BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Merck’s Keytruda Backslides After Failed Head and Neck Cancer Trial

  Merck’s Phase III trial studying Keytruda (pembrolizumab) for unresected locally advanced head and neck squamous cell carcinoma (HNSCC) failed to meet the primary endpoint.

  July 20, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Business

  Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026

  Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.

  July 20, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Monkeypox: Experts Urge Caution, Surveillance but Stop Short of Declaring Emergency

  As monkeypox continues to spread across the globe, health experts suggest monitoring vaccine effectiveness, population spread and at-risk groups.

  July 20, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Urovant is Getting Really Good at Urology: Specialization Leading to Innovation

  With a deep knowledge of the urology space, Urovant is developing a unique approach to treating overactive bladder - an injectable plasmid human cDNA encoding maxi-K channel gene therapy.

  July 20, 2022

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Drug Development

  VBL Becomes Latest Casualty in Heated Battle to Solve Ovarian Cancer

  VBL’s ofra-vec candidate was primarily evaluated on its ability to improve PFS and OS in study participants—and delivered disappointing results for both measures.

  July 20, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Genetown

  CAMP4 Brings $100M to Target the Dark Side of the Genome with regRNA Platform

  CAMP4 Therapeutics raised another $100 million in financing to advance its approach into the “dark side of the genome” and drive two therapeutics into clinical trials next year.

  July 20, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Global Roundup: Hansa, OSE Nab New Funding, F-Star Links with Takeda

  Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.

  July 20, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Career Advice

  5 Job Interview Techniques That Actually Work

  Finding a new job can be a daunting task. From updating your resume to preparing for interviews, there are a lot of moving parts. To help, here are five interview techniques that actually work.

  July 20, 2022

   · 

  4 min read

   · 

  Franklin Carpenter
• 

  Business

  Biogen Axes Schizophrenia Program, Touts Potential of Next Alzheimer’s Drug

  At Biogen’s quarterly conference call, outgoing CEO Michel Vounatsos emphasized a strong balance sheet and 10 exciting late-stage programs. The company also raised its 2022 guidance.

  July 20, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Policy

  Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna

  The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here’s a look at recent biopharma patent disputes.

  July 20, 2022

   · 

  3 min read

   · 

  Mark Terry